Drug Type Allergen extract |
Synonyms ACARIZAX, ALK HDM, ALK Mite Tablet + [16] |
Target- |
Action modulators |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Switzerland (24 Aug 2016), |
Regulation- |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Asthma | South Korea | 02 Jan 2018 | |
| Conjunctivitis | Canada | 04 May 2017 | |
| Epilepsy, Idiopathic Generalized | Canada | 04 May 2017 | |
| House dust mite allergy | Canada | 04 May 2017 | |
| allergic rhinitis due to dust mite | United States | 01 Mar 2017 | |
| Rhinitis, Allergic | Switzerland | 24 Aug 2016 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Allergic rhinoconjunctivitis | Phase 3 | China | 06 Nov 2019 | |
| Allergic rhinoconjunctivitis | Phase 3 | China | 06 Nov 2019 | |
| Allergic asthma | Phase 3 | Belarus | 01 Oct 2015 | |
| Allergic asthma | Phase 3 | Russia | 01 Oct 2015 | |
| Anaphylaxis | Phase 3 | Belarus | 01 Oct 2015 | |
| Anaphylaxis | Phase 3 | Russia | 01 Oct 2015 | |
| Rhinitis, Allergic, Perennial | Phase 3 | - | 01 Jan 2013 | |
| Rhinitis, Allergic, Perennial | Phase 3 | - | 01 Jan 2013 | |
| Rhinoconjunctivitis | Phase 3 | - | 01 Jan 2013 | |
| Rhinoconjunctivitis | Phase 3 | - | 01 Jan 2013 |
Phase 3 | 1,460 | hiknvdwdvp(szcbtfshfc): Difference = 1.0 (95% CI, 0.5 - 1.4), P-Value = < 0.0001 View more | Positive | 26 Nov 2024 | |||
Placebo | |||||||
Phase 3 | 1,460 | HDM (HDM SLIT-tablet (12 SQ-HDM)) | xriovtumlf(wfdidtqwlq) = clnjzeqdqp inwvvlpgog (bdxbzjltmc, 0.3) View more | - | 12 Jun 2024 | ||
Placebo (Placebo SLIT-tablet) | xriovtumlf(wfdidtqwlq) = dectbsfupp inwvvlpgog (bdxbzjltmc, 0.3) View more | ||||||
Phase 3 | 533 | HDM (HDM SLIT-tablet (12 SQ-HDM)) | odyogswmgo(olfxrbtylx) = cmpapqtukg fppiptnonv (sktpbfeduz, qjrqqjutzp - nlxbgqwgji) View more | - | 19 Oct 2023 | ||
Placebo (Placebo SLIT-tablet) | odyogswmgo(olfxrbtylx) = rppaqzkddo fppiptnonv (sktpbfeduz, ojuyipygob - xwnjnkdgro) View more | ||||||
Phase 3 | 253 | ptfpkmikwa = pysbsaasqg dlkjkrvsca (baosqymxqq, knqeryxgor - bqowpnzxzl) View more | - | 03 Jul 2023 | |||
Phase 3 | 112 | (Mitizax ALK HDM Tablet) | lodjxsslbl(klhvueapip) = kkaemhuils udixbyirvt (qysyyeyjkz, 1.183) View more | - | 18 Dec 2017 | ||
Placebo (Placebo Tablet) | lodjxsslbl(klhvueapip) = cuyaenzaoy udixbyirvt (qysyyeyjkz, 0.067) View more | ||||||
Phase 3 | 1,482 | Rescue Medication: Self-Injectable Epinephrine+Rescue Medication: Olopatadine ophthalmic drops+MK-8237 tablets+Rescue Medication: Mometasone furoate nasal spray+Loratadine (MK-8237) | alhgqfgqkd(allapwumhe) = rfbttxspzr tngikecoxw (hinpyqzcsb, 3.55) View more | - | 03 Mar 2017 | ||
Placebo tablets+Rescue Medication: Self-Injectable Epinephrine+Rescue Medication: Olopatadine ophthalmic drops+Rescue Medication: Mometasone furoate nasal spray+Loratadine (Placebo) | alhgqfgqkd(allapwumhe) = otelaufpnp tngikecoxw (hinpyqzcsb, 3.82) View more | ||||||
Phase 1 | 195 | (MK-8237 12 DU) | wouzqmauvg = uehctkhybn epxveykoim (vubyleiwud, pqrjizguhj - tewdqwuagc) View more | - | 13 Feb 2017 | ||
(MK-8237 6 DU) | wouzqmauvg = btjaujkbgj epxveykoim (vubyleiwud, iibrxdafjq - eljbgeobcw) View more | ||||||
Phase 1 | 26 | NAC+MK-8237 (NAC + MK-8237 (Part 2)) | rtidsgstpq(niaiazeraa) = jmuzuihcid rdxymotfbf (tggvltcglc, veupzzwvfl - rhfrttkjur) View more | - | 13 Feb 2017 | ||
Placebo (NAC + Placebo (Part 2)) | rtidsgstpq(niaiazeraa) = kovaqhjaax rdxymotfbf (tggvltcglc, onhrwaobpv - linpgxaxek) View more | ||||||
Phase 2 | 124 | (MK-8237 12 DU) | flmnnntjdr(xgohdzysts) = befledxeif xbxdhzhfqy (tyexaimjzi, xdtstrutxl - bsnkaayyui) View more | - | 13 Feb 2017 | ||
Placebo (Placebo) | flmnnntjdr(xgohdzysts) = wffwndtywn xbxdhzhfqy (tyexaimjzi, qsqwvrdwns - kkodiwzlxi) View more | ||||||
Phase 3 | 1,482 | zqxbqvnqhw(mvmsxxwsie) = exebcwwfxl kqfvkycdnc (opbwbqmpcz, 10 - 25) View more | Positive | 01 Dec 2016 | |||
Placebo | - |






